DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2009/0082338A1 Mizuno Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2009/0082338A1 Mizuno Et Al US 20090082338A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0082338A1 Mizuno et al. (43) Pub. Date: Mar. 26, 2009 (54) PREVENTIVE OR REMEDY FOR (86). PCT No.: PCT/UP2006/312266 GLAUCOMA S371 (c)(1), 2), (4) Date: Dec. 19, 2007 (75) Inventors: Ken Mizuno, Tokyo (JP); Jiro (2), (4) . Matsumoto, Saitama (JP) (30) Foreign Application Priority Data Jun. 21, 2005 (JP) ................................. 2005-180535 Correspondence Address: Publication Classification OBLON, SPIVAK, MCCLELLAND MAIER & NEUSTADT, P.C. (51) Int. Cl. 194O DUKE STREET A6II 3/55 (2006.01) ALEXANDRIA, VA 22314 (US) A63/496 (2006.01) A6IP27/06 (2006.01) - 0 (52) U.S. Cl. .................................... 514/218: 514/253.05 (73) Assignee: so Co., Ltd., Nagoya-shi, Aichi (57) ABSTRACT There is provided a preventive for glaucoma or a preventive or a remedy for ocular hypertension, with a potent ocular (21) Appl. No.:y x- - - 11A993,1019 hypotensivey effect and prolongedyp duration thereof.p A preven tive or a remedy for glaucoma comprising a Rho kinase (22) PCT Filed: Jun. 20, 2006 inhibitor and an C. blocker in combination. Patent Application Publication Mar. 26, 2009 US 2009/0082338A1 Fig. 1 S S 5 Y D f CO 1. n n1 C - d O: H Z l O CD 2 Y S O - Fig. 2 TIME US 2009/0082338 A1 Mar. 26, 2009 PREVENTIVE OR REMEDY FOR nism of action (Patent Documents 1 and 2). Rho kinase GLAUCOMA inhibitors lower IOP by promoting aqueous outflow from the trabecular outflow pathway (Non-patent Document 2), and it TECHNICAL FIELD is further suggested that this action may be attributed to changes in the cytoskeleton of a trabecular meshwork cells 0001. The present invention relates to a preventive or a (Non-patent Documents 2 and 3). remedy for glaucoma or ocular hypertension. 0008. In the treatment of glaucoma and ocular hyperten Sion, drugs having an ocular hypotensive action are used in BACKGROUND ART combination to enhance the additive ocular hypotensive 0002 Glaucoma is a disease characterized by the elevation effects. For example, combination use of a prostaglandin and of intraocular pressure (IOP) due to various pathogenesis a sympathetic nerve blocker (Patent Document 3), or a com leads to damage and atrophy of the optic nerve resulting in the bination of some drugs having an ocular hypotensive action abnormal visual field, and thus visual acuity is gradually (Patent Document 4), and the like have been reported. Fur reduced. Since the optic nerve does not recover once atrophy thermore, combination use of a Rho kinase inhibitor and a B occurs, glaucoma is a refractory disease in that not only vision blocker (Patent Document 5) and a remedy for glaucoma is lost if glaucoma is untreated, but also the condition is only comprising a Rho kinase inhibitor and a prostaglandin in maintained even after Successful treatment, and recovery can combination (Patent Document 6) have also been reported. not be expected. Furthermore, ocular hypertension, which 0009. However, the above-mentioned known remedies may lead to development of glaucoma over a long time and therapies for glaucoma and ocular hypertension are far although in the absence of visual field defects, also has a from satisfactory in view of the potency of the ocular similar risk. hypotensive effect and the duration of action. In particular, it 0003 Glaucoma is classified into three types: congenital is more difficult to lower normal IOP in patients with normal (developmental) glaucoma, secondary glaucoma, and pri tension glaucoma rather than lower elevated IOP. The above mary glaucoma. Patients with congenital (developmental) mentioned existing drugs and combinations thereof have glaucoma are born with growth deficiency of the iridocorneal limitations in the treatment of normal tension glaucoma, and angle, and obstruction of the aqueous outflow causes this type enhancement of the ocular hypotensive action is needed in the of glaucoma. Secondary glaucoma arises as a result of inflam clinical setting. mation or injury and is caused by Such as uveitis or ocular 0010 Under such circumstances, there has been no report trauma as well as hemorrhage due to diabetes, long-term use on glaucoma treatment using a Rho kinase inhibitor and a of steroid hormones for the treatment of other diseases, and selective sympathetic nerve C. receptor blocking agent in the like. Primary glaucoma is a generic name of glaucomas of combination, and there has been no description about the types with unclear causes and occurs most commonly of cooperative effect of Such a combination. glaucomas, with a high incidence among middle aged and O011 Patent Document 1 WO00/09162 elderly persons. Primary glaucoma and secondary glaucoma 0012 Patent Document 2.JP-A-11-349482 are further Subdivided into two types, open-angle glaucoma (0013 Patent Document 3 Japanese Patent No. 2726672 and angle-closure glaucoma, depending on the blockage of 0014 Patent Document 4 WO02/38158 the aqueous outflow. While many patients develop normal 00.15 Patent Document 5 JP-A-2004-182723 tension glaucoma in the absence of elevated IOP, the primary 0016 Patent Document 6.JP-A-2004-107335 aim of glaucoma treatment is to lower the IOP 0017 Non-patent Document 1 Journal of Japanese Oph 0004 For the treatment of glaucoma, laser treatment (laser thalmological Society, 94(8), 762-768 (1990) trabeculoplasty), Surgical therapy (trabeculectomy or trabe (0018 Non-patent Document 2 IOVS, 42(1), 137-144 culotomy), or the like is performed when IOP cannot be (2001) controlled with a drug or a patient with angle-closure glau 0019 Non-patent Document 3) IOVS, 42(5), 1029-1037 coma has an acute glaucoma attack, but drug therapy is used (2001) as the first line therapy. 0005 Drugs used in the drug therapy of glaucoma include DISCLOSURE OF THE INVENTION sympathetic nerve stimulants (nonselective stimulants such 0020. An object of the present invention is to provide a as epinephrine and C stimulants such as apraclonidine), sym preventive or a remedy for glaucoma or ocular hypertension pathetic nerve blockers (B blockers such as timolol. with a potent ocular hypotensive effect and a prolonged dura befunolol, carteolol, nipradillol, betaxolol, levobunolol, and tion of action. metipranolol and C. blockers such as bunaZosin hydrochlo 0021. The inventors of the present invention conducted ride), parasympathetic nerve agonists (pilocarpine, etc.), car various researches in order to achieve the foregoing object. As bonic anhydrase inhibitors (acetazolamide, etc.), prostaglan a result, we have found that a potent ocular hypotensive effect dins (isopropyl unoprostone, latanoprost, travoprost, is exerted by administering a Rho kinase inhibitor and an O. bimatoprost, etc.), and so forth. blocker in combination, and the duration of action is pro 0006. Of these, bunaZosin hydrochloride is a drug first longed. developed as an agent for selectively blocking sympathetic 0022 Specifically, the present invention relates to the fol nerve C. receptors, unlike existing remedies for glaucoma. As lowings. its mechanism of action, bunaZosinhydrochloride locally acts 0023, 1) A preventive or a remedy for glaucoma compris on the eyes by instillation and lowers IOP by promoting ing a Rho kinase inhibitor and an O. blocker in combina aqueous outflow from the uveoscleral outflow pathway (Non tion. patent Document 1). 0024. 2) A preventive or a remedy for ocular hypertension 0007 Meanwhile, Rho kinase inhibitors have been found comprising a Rho kinase inhibitor and an C. blocker in as candidate remedies for glaucoma based on a novel mecha combination. US 2009/0082338 A1 Mar. 26, 2009 0025, 3) Use of a Rho kinase inhibitor and an C. blocker in a Rhokinase inhibiting action and can be produced by known combination for production of a preventive or a remedy for methods such as, for example, the method described in glaucoma. WO99f2O62O. 0026 4) Use of a Rhokinase inhibitor and an O blocker in 0036 Hexahydro-1-(5-isoquinolinesulfonyl)-1H-1,4-di combination for production of a preventive or a remedy for azepine can be produced by known methods such as, for ocular hypertension. example, the method described in JP-A-61-227581 and, fur 0027 5) A method for preventing or treating glaucoma, ther, can be purchased and used as a drug (Eril.R S Injection wherein the method comprises administratinga Rhokinase nonproprietary name: fasudil hydrochloride hydrate, Asahi inhibitor and an O blocker in combination. Kasei Pharma). 0028 6) A method for preventing or treating ocular hyper 0037. Furthermore, Y-39983 is known to lower IOP in tension, wherein the method comprises administrating a rabbits with normal IOP from 1 hour after instillation, shows Rho kinase inhibitor and an C. blocker in combination. the maximum ocular hypotensive effect at 2 to 4 hours after 0029. According to the present invention, a preventive or a instillation, and has a potent action dependent on the concen remedy for glaucoma or ocular hypertension with a potent tration, with the maximum IOP reduction of 15 mmHg at a ocular hypotensive effect and a prolonged duration of action concentration of 0.1% (BIO Clinica, 1713), 1191-1194 can be provided. 2002: The 4th Int. Symp. Ocular Pharmacol. Pharm. Feb. 28, 2002, Seville 2002: 2: Annu. Meet. Assoc. Res. Vision BRIEF DESCRIPTION OF THE DRAWINGS Ophthalmol. May 1, 2005, Fort Lauderdale 2005: Abst. 3787/B145). 0030 FIG. 1 is a graph showing changes in IOP over time 0038 Examples of salts of (S)-(-)-1-(4-fluoro-5-iso in each treatment group. IOP is shown as a change from the quinolinesulfonyl)-2-methyl-1,4-homopiperazine and initial IOP (meantstandard error). O, bunaZosin alone group; hexahydro-1-(5-isoquinolinesulfonyl)-1H-1,4-diazepine , (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1, include pharmaceutically acceptable salts such as salts of 4-homopiperazine alone group; A, bunaZosin plus (S)-(-)-1- inorganic acids Such as hydrochloric acid, Sulfuric acid, nitric (4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopip acid, hydrofluoric acid, and hydrobromic acid and salts of erazine group.
Load more

Recommended publications
  • Mechanism of Action of Nicotine in Isolated Urinary Bladder of Guinea-Pig
    Br. J. Pharmacol. (1988), 95, 465-472 Mechanism of action of nicotine in isolated urinary bladder of guinea-pig Tetsuhiro Hisayama, Michiko Shinkai, lIssei Takayanagi & Toshie Toyoda Department of Chemical Pharmacology, Toho University School of Pharmaceutical Sciences, 2-2-1, Miyama, Funabashi, Chiba 274, Japan 1 Nicotine produced a transient contraction of isolated strips of guinea-pig urinary bladder. The response to nicotine was antagonized by the nicotinic receptor antagonist, hexamethonium but was insensitive to tetrodotoxin. 2 The nicotine-induced contraction was potentiated by the cholinesterase inhibitor, physostig- mine, and was reduced to 50% and 70% by the muscarinic cholinoceptor antagonist, atropine and the sympathetic neurone blocking drug, guanethidine, respectively. Chemical denervation with 6- hydroxydopamine abolished the inhibitory effect of guanethidine. Simultaneous treatment with atropine and guanethidine did not abolish the response to nicotine, but the degree of inhibition was comparable to that obtained with atropine alone. 3 The nicotine-induced contraction was insensitive to bunazosin and yohimbine (al- and Cc2-adrenoceptor antagonists, respectively), and exogenously applied noradrenaline did not cause a contraction even in the presence of blockade of noradrenaline uptake mechanisms with desipramine and normetanephrine and of fi-adrenoceptors with propranolol, suggesting a non-adrenergic nature of the sympathomimetic effect of nicotine in this tissue. 4 The nicotine-induced contraction in the presence of atropine was abolished after desensitization of P2-purinoceptors with a, ,B-methylene adenosine 5'-triphosphate, a slowly degradable ATP ana- logue selective for P2-purinoceptors. By this desensitization, the response to ATP, but not to hista- mine, was also abolished. 5 A cyclo-oxygenase inhibitor flurbiprofen partially inhibited the nicotine-induced contraction.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Antihypertensive Agents Using ALZET Osmotic Pumps
    ALZET® Bibliography References on the Administration of Antihypertensive Agents Using ALZET Osmotic Pumps 1. Atenolol Q7652: W. B. Zhao, et al. Stimulation of beta-adrenoceptors up-regulates cardiac expression of galectin-3 and BIM through the Hippo signalling pathway. British Journal of Pharmacology 2019;176(14):2465-2481 Agents: Isoproterenol; propranolol; carvedilol; atenolol; ICI-118551 Vehicle: saline; ascorbic acid, buffered; Route: SC; Species: Mice; Pump: 2001; Duration: 1 day; 2 days; 7 days; ALZET Comments: Dose ((ISO 0.6, 6, 20 mg/kg/d), (Prop 2 mg/kg/d), (Carv 2 mg/kg/d), (AT 2 mg/kg/d), (ICI 1 mg/kg/d)); saline with 0.4 mM ascorbic acid used; Controls were non-transgenic and received mp w/ vehicle; animal info (12-16 weeks, Male, (C57BL/6J, beta2-TG, Mst1-TG, or dnMst1-TG)); ICI-118551 is a beta2-antagonist with the structure (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; cardiovascular; Minipumps were removed to allow for washout of ISO overnight prior to imaging; Q7241: M. N. Nguyen, et al. Mechanisms responsible for increased circulating levels of galectin-3 in cardiomyopathy and heart failure. Sci Rep 2018;8(1):8213 Agents: Isoproterenol, Atenolol, ICI-118551 Vehicle: Saline, ascorbic acid; Route: SC; Species: Mice; Pump: Not Stated; Duration: 48 Hours; ALZET Comments: Dose: ISO (2, 6 or 30 mg/kg/day; atenolol (2 mg/kg/day), ICI-118551 (1 mg/kg/day); 0.4 mM ascorbic used; animal info (12 14 week-old C57Bl/6 mice); cardiovascular; Q6161: C.
    [Show full text]
  • Jp Xvii the Japanese Pharmacopoeia
    JP XVII THE JAPANESE PHARMACOPOEIA SEVENTEENTH EDITION Official from April 1, 2016 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the convenience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 64 Pursuant to Paragraph 1, Article 41 of the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices (Law No. 145, 1960), the Japanese Pharmacopoeia (Ministerial Notification No. 65, 2011), which has been established as follows*, shall be applied on April 1, 2016. However, in the case of drugs which are listed in the Pharmacopoeia (hereinafter referred to as ``previ- ous Pharmacopoeia'') [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as ``new Pharmacopoeia'')] and have been approved as of April 1, 2016 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as of March 31, 2016 as those exempted from marketing approval pursuant to Paragraph 1, Article 14 of the Same Law (hereinafter referred to as ``drugs exempted from approval'')], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on September 30, 2017.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Penetration Enhancers in Ocular Drug Delivery
    pharmaceutics Review Penetration Enhancers in Ocular Drug Delivery Roman V. Moiseev 1 , Peter W. J. Morrison 1 , Fraser Steele 2 and Vitaliy V. Khutoryanskiy 1,* 1 Reading School of Pharmacy, University of Reading, Whiteknights, P.O. Box 224, Reading RG66AD, UK 2 MC2 Therapeutics, James House, Emlyn Lane, Leatherhead KT22 7EP, UK * Correspondence: [email protected]; Tel.: +44-(0)-118-378-6119 Received: 30 May 2019; Accepted: 3 July 2019; Published: 9 July 2019 Abstract: There are more than 100 recognized disorders of the eye. This makes the development of advanced ocular formulations an important topic in pharmaceutical science. One of the ways to improve drug delivery to the eye is the use of penetration enhancers. These are defined as compounds capable of enhancing drug permeability across ocular membranes. This review paper provides an overview of anatomical and physiological features of the eye and discusses some common ophthalmological conditions and permeability of ocular membranes. The review also presents the analysis of literature on the use of penetration-enhancing compounds (cyclodextrins, chelating agents, crown ethers, bile acids and bile salts, cell-penetrating peptides, and other amphiphilic compounds) in ocular drug delivery, describing their properties and modes of action. Keywords: ocular drug delivery; cornea; penetration enhancers; ocular conditions; ophthalmology 1. Introduction According to the World Health Organization, the number of people who live with some form of distance or near vision impairment is about 1.3 billion worldwide [1]. This problem is very important because approximately 80% of external input of information delivered to the brain is processed by the visual pathway [2].
    [Show full text]
  • Poison Act 1952
    LAWS OF MALAYSIA _____________ ONLINE VERSION OF UPDATED TEXT OF REPRINT _____________ Act 366 POISONS ACT 1952 As at 1 February 2019 2 POISONS ACT 1952 First enacted … … … … 1952 (Ord. No. 29 of 1952) Revised … … … … 1989 (Act 366 w.e.f. 13 April 1989) Latest amendment made by P.U. (A) 8/2019 which came into operation on … … 10 January 2019 PREVIOUS REPRINTS First Reprint ... ... ... ... ... 2001 Second Reprint ... ... ... ... ... 2006 3 LAWS OF MALAYSIA Act 366 POISONS ACT 1952 ARRANGEMENT OF SECTIONS Section 1. Short title and application 2. Interpretation 3. Establishment of Poisons Board 4. Proceedings of Board 5. Powers of Board to regulate proceedings 6. Power of Minister to amend Poisons List 7. Application of the Act 8. Control of imports of poisons 9. Packaging, labelling and storing of poisons 10. Transport of poisons 11. Control of manufacture of preparations containing poison 12. Control of compounding of poisons for use in medical treatment 13. Possession for sale of poison and sale of poison in contravention of this Act an offence 14. Control of acetylating substances 15. Sale of poisons by wholesale 16. Sale of poisons by retail 17. Prohibition of sale to persons under 18 18. Restriction on the sale of Part I poisons generally 19. Supply of poisons for the purpose of treatment by professional men 20. Group A Poisons 21. Group B Poisons 4 Laws of Malaysia ACT 366 Section 22. Group C Poisons 23. Group D Poisons 24. Prescription book 25. Sale of Part II Poisons 26. Licences 27. Register of licences 28. Annual list to be published 29.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev
    Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE
    [Show full text]
  • Prescription Medications, Drugs, Herbs & Chemicals Associated With
    Prescription Medications, Drugs, Herbs & Chemicals Associated with Tinnitus American Tinnitus Association Prescription Medications, Drugs, Herbs & Chemicals Associated with Tinnitus All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form, or by any means, without the prior written permission of the American Tinnitus Association. ©2013 American Tinnitus Association Prescription Medications, Drugs, Herbs & Chemicals Associated with Tinnitus American Tinnitus Association This document is to be utilized as a conversation tool with your health care provider and is by no means a “complete” listing. Anyone reading this list of ototoxic drugs is strongly advised NOT to discontinue taking any prescribed medication without first contacting the prescribing physician. Just because a drug is listed does not mean that you will automatically get tinnitus, or exacerbate exisiting tinnitus, if you take it. A few will, but many will not. Whether or not you eperience tinnitus after taking one of the listed drugs or herbals, or after being exposed to one of the listed chemicals, depends on many factors ‐ such as your own body chemistry, your sensitivity to drugs, the dose you take, or the length of time you take the drug. It is important to note that there may be drugs NOT listed here that could still cause tinnitus. Although this list is one of the most complete listings of drugs associated with tinnitus, no list of this kind can ever be totally complete – therefore use it as a guide and resource, but do not take it as the final word. The drug brand name is italicized and is followed by the generic drug name in bold.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]